Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002369 · ClinicalTrials.gov registry record · NA
A Comparison of Epivir Plus Crixivan Combined With Zerit or Retrovir in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs
A NA study of HIV Infections, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- NA
- Development phase
- 200
- Enrollment target
- 11
- Study locations
NCT00002369: Completed NA study of HIV Infections, sponsored by Bristol-Myers Squibb.
NCT00002369 is a NA study of HIV Infections that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 200 participants, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (55% lower). The trial reports 11 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002369, a NA study of HIV Infections, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- NA
- Development phase
- 200 participants
- Enrollment target
- 11
- Study locations
Study Summary
To evaluate the tolerance, and comparative virologic and immunologic effects of the two combination regimens.
Conditions Studied
Interventions
- DRUG Zidovudine
- DRUG Lamivudine
- DRUG Indinavir sulfate
- DRUG Stavudine
Study Locations (11)
Florida
- HIV Clinical Research Ctr - Fort Lauderdale
- Infectious Disease Research Institute Inc - Tampa
Massachusetts
- Boston Univ Med Ctr Hosp / Evans - 556 - Boston
- Community Research Initiative of New England - Brookline
Other
- Hosp Regional de Ponce - Area Vieja - Ponce
- San Juan AIDS Program - Santurce
Alabama
- Univ of Alabama at Birmingham - Birmingham
Georgia
- Advance Clinical Research - Atlanta
Louisiana
- Louisiana State Univ Med Ctr / HIV Outpatient Clinic - New Orleans
Missouri
- Washington Univ School of Medicine - St Louis
Texas
- Blackstock Family Health Ctr - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Phase | NA |
What the finished NCT00002369 record still lists
NCT00002369 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (55% lower).
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 4 interventions - of which Zidovudine is the first listed.
NCT00002369 lists 11 locations in 8 states (Florida, Massachusetts, Other).
Frequently Asked Questions
What is clinical trial NCT00002369 about?
NCT00002369 is a clinical study titled "A Comparison of Epivir Plus Crixivan Combined With Zerit or Retrovir in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs". To evaluate the tolerance, and comparative virologic and immunologic effects of the two combination regimens.
What is the current status of trial NCT00002369?
This trial is currently completed. It is a NA study. The enrollment target is 200 participants.
What conditions does trial NCT00002369 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00002369?
The interventions under investigation include: Zidovudine (DRUG), Lamivudine (DRUG), Indinavir sulfate (DRUG), Stavudine (DRUG).
Who is sponsoring clinical trial NCT00002369?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002369 being conducted?
This trial has 11 study locations across Alabama, Florida, Georgia, Louisiana, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00002369's enrollment target sits among peer trials
200 171st of 542 higher than 362 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk
RECRUITING · NA
-
Community-based Education, Navigation, and Support Intervention for Military Veterans
RECRUITING · NA
-
WiseApp for Spanish Speakers Living With HIV
RECRUITING · NA
-
Comprehensive HIV and Harm Prevention Via Telehealth
RECRUITING · NA
-
Substance Checking Outreach and Pre-Exposure Prophylaxis (PrEP) Engagement Study
RECRUITING · NA
-
Food as Medicine for HIV and Diabetes
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes